IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
CROI 2017: Prednisone Reduces Risk of Developing TB-IRIS after Starting Antiretroviral Treatment
- Details
- Category: Tuberculosis (TB)
- Published on Wednesday, 08 March 2017 00:00
- Written by Keith Alcorn
Prednisone reduces the risk of immune restoration inflammatory syndrome (IRIS) in people with HIV after starting tuberculosis (TB) treatment, a randomized trial called PredART has found. The results were presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle by Graeme Meintjes from the University of Cape Town in South Africa.
CROI 2017: Triple Tuberculosis Regimen Beats XDR-TB in First Trial
- Details
- Category: Tuberculosis (TB)
- Published on Monday, 20 February 2017 00:00
- Written by Keith Alcorn
A regimen of three oral drugs given for 6 months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Francesca Conradie of Sizwe Tropical Disease Hospital in Johannesburg reported at the 2017 Conference on Retroviruses and Opportunistic Infections last week in Seattle. If the results are replicated in a larger population, the findings could revolutionize the prospects for treating not just XDR-TB, but also more severe cases of multidrug-resistant tuberculosis (MDR-TB).
CROI 2017: Isoniazid Preventive Therapy for TB Reduces Risk of Death for People Living with HIV
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 28 February 2017 00:00
- Written by Keith Alcorn
A 6-month course of isoniazid preventive treatment (IPT) for at the beginning of the Temprano trial in Ivory Coast reduced the risk of death by 37% over a mean follow-up period of 4.5 years, Anani Badje reported at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
AIDS 2016: Neglect of Infectious Disease in Prisons Highlighted at Conference
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Wednesday, 07 September 2016 00:00
- Written by Theo Smart
A special issue of The Lancet was published to coincide with the recent 21st International AIDS Conference in Durban, containing a comprehensive seriesof reviews on the burden of HIV, hepatitis B, hepatitis C, and tuberculosis (TB) among prisoners worldwide.
More Articles...
- AIDS 2016: New WHO Algorithm Aims to Prevent TB Deaths in People with Advanced HIV
- AIDS 2016: High-Dose Rifampicin for TB May Improve Survival of HIV+ People with Low CD4 Counts
- AIDS 2016: Does Detectable CMV Signal High Mortality Risk for Older People with HIV and TB?
- AIDS 2016: Training Community Health Workers Leads to Surge in TB Diagnoses in Malawi
Web Design and Development by